California-based Tryp Therapeutics joins other sector leaders with Phase II clinical trials Tryp’s strategy isn’t to steward its drug candidates right through to an FDA approval. Rather, the company hopes to demonstrate their efficacy in the treatment of a range of neuropsychiatric and chronic pain conditions via Phase 2a proof of concept trials, which it understands to be the value inflection…


Previous articleAlberta’s First Full-Service Psychedelic Therapy Clinic Opens in Calgary, Ushering in a New Era of Hope to Deal with the Growing Mental Health Crisis in Canada
Next articlePure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Delineates Parameters and Timeline of Study into Psilocybin-Based Active Treatments